Cardlytics Seeks Shareholder Approval for Reverse Stock Split to Avoid Nasdaq Delisting
summarizeSummary
Cardlytics is seeking shareholder approval for a reverse stock split (1-for-5 to 1-for-15) to meet Nasdaq's minimum bid price requirement and avoid delisting, following a year of significant revenue decline and impairment.
check_boxKey Events
-
Shareholder Vote on Reverse Stock Split
Shareholders will vote on a proposal to effect a reverse stock split of common stock at a ratio ranging from 1-for-5 to 1-for-15, with the Board of Directors having discretion over the final ratio.
-
Aims to Maintain Nasdaq Listing
The primary purpose of the reverse stock split is to increase the per-share price to meet Nasdaq's $1.00 minimum bid price requirement and avoid potential delisting, a critical step given the current stock price of $0.98.
-
Addresses Prior Underperformance
This proposal comes after the company reported a 16% revenue decline and a $49.1 million goodwill impairment in its 2025 Annual Report, highlighting the financial challenges leading to the need for this action.
-
Routine Governance Matters
Other proposals include the election of three Class II directors (Amit Gupta, Jack Klinck, Srishti Gupta), the ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
auto_awesomeAnalysis
Cardlytics, Inc. has filed its definitive proxy statement (DEF 14A) for its Annual Meeting on May 20, 2026. The most significant proposal is a request for shareholder approval to amend the company's charter to effect a reverse stock split at a ratio between 1-for-5 and 1-for-15. This action is primarily aimed at increasing the per-share market price of the common stock to meet Nasdaq's minimum bid price requirement of $1.00, thereby preventing delisting. The need for a reverse stock split follows a challenging period, as indicated by the company's 2025 revenue decline of 16% and a $49.1 million goodwill impairment, as reported in its recent 10-K. While a reverse split is a necessary step to maintain listing and potentially improve marketability, it reflects significant past stock underperformance and carries risks, including no guarantee of a sustained price increase or improved liquidity. The Board will have discretion over the exact ratio and implementation. Other proposals include the routine election of three Class II directors, ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
At the time of this filing, CDLX was trading at $0.98 on NASDAQ in the Technology sector, with a market capitalization of approximately $53.3M. The 52-week trading range was $0.66 to $3.28. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.